In our laboratory, we focus on the following research projects.
1 . The research to optimize the drug prescription for each patient based on pharmacokinetics analysis in collaboration with hospitals and other clinical facilities. Our combined analysis of pharmacokinetics using therapeutic drug monitoring by HPLC and LC-MS/MS could be applicable to investigate the relationship between these pharmacokinetic factors and clinical outcome during drug therapy.
2 . The research related to new psychoactive substrates (NPSs) in collaboration with several research facilities and local government, we try to establish the systems to monitor and identify NPSs and their metabolites in order to prevent their illegal use. We also plan to find out the mechanisms of actions of NPSs.
3 . The research to investigate the pharmacokinetic properties and the safety of drugs and functional food ingredients in collaboration with several companies. We investigate the pharmacokinetic properties, the drug-food interaction and the mechanisms of drug delivery system, and assess the controlled-release of drugs using novel materials in order to promote the appropriate use of drugs and to develop new functional foods.
研究課題 Research Objectives
各種薬物測定系の確立と能動的な薬物治療への関与を目指した基礎および臨床の統合的研究 To establish the systems of therapeutic drug monitoring and its application in clinical in order for clinical pharmacists to be positively involved in pharmacological therapy
危険ドラッグおよびその代謝物の検出 / 同定と作用メカニズムに関する研究 To establish the methods for monitoring and identifying NPSs and their metabolites and to elucidate their mechanisms of actions
薬剤および健康食品素材の生体内挙動と安全性評価に関する研究 To investigate the pharmacokinetic properties and the safety of drugs and functional food ingredients
最近の研究成果 Research Results
Ohi K., Nishizawa D., Sugiyama S., Takai K., Fujikane D., Kuramitsu A., Hasegawa J., Soda M., Kitaichi K., Hashimoto R., Ikeda K., Shioiri T., Cognitive Performances across Individuals at High Genetic Risk for Schizophrenia, High Genetic Risk for Bipolar Disorder, and Low Genetic Risks: A Combined Polygenic Risk Score Approach. Psychological Med., in press.
Ito S, Mori M, Matsuo M, Yamasaki R, Oida Y, Soda M, Kitaichi K. The establishment to measure oxycodone in plasma with liquid chromatography‐tandem mass spectrometry. Neuropsychopharmacol Rep., 42, 299-305 (2022).
Kushima I., ... Ohi K., ... Kitaichi K., ...Ozaki N. (89 authors). Cross-Disorder Analysis of Genic and Regulatory Copy Number Variations in Bipolar Disorder, Schizophrenia, and Autism Spectrum Disorder. Biol Psychiat., 92, 362-374 (2022).
Sadaka Y., Soda M., Hori A., Miyahara Y., Oida Y., Nishigaki Y., Tomita E., Mizui T., Kitaichi K. Combined Use of Calcium-channel Blockers With Ombitasvir/Paritaprevir/Ritonavir Exacerbates Peripheral Edema in Elderly Japanese Patients. Anticancer Res., 42, 2087-2093 (2022).
Kadomura N., Ito T., Kawashima H., Matsuhisa T., Kinoshita T., Soda M., Kohyama E., Iwaki T., Nagai H., Kitaichi K. In vitro metabolic profiles of adamantyl positional isomers of synthetic cannabinoids. Forensic Toxicol., 39, 26-44 (2021).
Hori A., Sahashi H., Sano S., Matsumiya E., Ariga M., Asano A., Soda M., Goto C., Mizui T., Komeda H., Kitaichi K. Efficacy and safety of enzalutamide in a real-world cohort of Japanese patients with castration-resistant prostate cancer. Anticancer Res., 40, 7101-7108 (2020).
